This is a preview of subscription content, log in via an institution to check access.
Reference
Deenen MJ, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. Journal of Clinical Oncology : 16 Nov 2015. Available from: URL: http://doi.org/10.1200/JCO.2015.63.1325
Rights and permissions
About this article
Cite this article
DPYD*2A-guided fluoropyrimidine therapy reduces costs. PharmacoEcon Outcomes News 742, 18 (2015). https://doi.org/10.1007/s40274-015-2646-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2646-0